{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:01:32Z","timestamp":1793325692445,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2024HXFH001"],"award-info":[{"award-number":["2024HXFH001"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["23NSFSC1836"],"award-info":[{"award-number":["23NSFSC1836"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.prp.2025.155824","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T12:00:12Z","timestamp":1737979212000},"page":"155824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Clinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: A case series and review of the literature"],"prefix":"10.1016","volume":"266","author":[{"given":"Qianqian","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2025.155824_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VFGF signaling a d associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.prp.2025.155824_bib2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.prp.2025.155824_bib3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/his.13716","article-title":"Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy","volume":"73","author":"Pfister","year":"2018","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.prp.2025.155824_bib4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","article-title":"Bevacizumab-associated glomerular microangiopathy","volume":"32","author":"Person","year":"2019","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2025.155824_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study","volume":"29","author":"Vigneau","year":"2014","journal-title":"Nephrol. Dial. Transpl."},{"issue":"9","key":"10.1016\/j.prp.2025.155824_bib6","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","article-title":"Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature","volume":"45","author":"Usui","year":"2014","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2025.155824_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00428-021-03114-5","article-title":"Lenvatinib-related renal microangiopathy: a case series","volume":"480","author":"Delsante","year":"2022","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.prp.2025.155824_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00428-023-03545-2","article-title":"Surufatinib-induced renal thrombotic microangiopathy: first case report and review of literature","volume":"483","author":"Zhu","year":"2023","journal-title":"Virchows Arch."},{"issue":"2","key":"10.1016\/j.prp.2025.155824_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangi\u00e9","year":"2007","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.prp.2025.155824_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ncpneph0476","article-title":"Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma","volume":"3","author":"Roncone","year":"2007","journal-title":"Nat. Clin. Pr. Nephrol."},{"issue":"3","key":"10.1016\/j.prp.2025.155824_bib11","first-page":"154","article-title":"Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation","volume":"1","author":"Levey","year":"2008","journal-title":"NDT"},{"issue":"2","key":"10.1016\/j.prp.2025.155824_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Boll\u00e9e","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib13","first-page":"36","article-title":"Progressive bevacizumab-associated renal thrombotic microangiopathy","volume":"2","author":"Uy","year":"2009","journal-title":"NDT"},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/0971-4065.107215","article-title":"Sunitinib induced nephrotic syndrome and thrombotic microangiopathy","volume":"23","author":"Jha","year":"2013","journal-title":"Indian J. Nephrol."},{"issue":"2","key":"10.1016\/j.prp.2025.155824_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.prp.2025.155824_bib16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00467-016-3355-z","article-title":"Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome","volume":"31","author":"Y\u0131lmaz","year":"2016","journal-title":"Pedia Nephrol."},{"issue":"4","key":"10.1016\/j.prp.2025.155824_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/nep.13072","article-title":"Renal thrombotic microangiopathy caused by bevacizumab","volume":"23","author":"Horino","year":"2018","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"10.1016\/j.prp.2025.155824_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1159\/000494080","article-title":"Thrombotic microangiopathy with severe proteinuria induced by lenvatinib for radioactive iodine-refractory papillary thyroid carcinoma","volume":"11","author":"Hyogo","year":"2018","journal-title":"Case Rep. Oncol."},{"issue":"45","key":"10.1016\/j.prp.2025.155824_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017870","article-title":"Bevacizumab-induced immunoglobulin A vasculitis with nephritis: a case report","volume":"98","author":"Endo","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10157-018-1596-9","article-title":"Bevacizumab-induced thrombotic microangiopathy and nephrotic syndrome","volume":"23","author":"Shimamura","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"issue":"2","key":"10.1016\/j.prp.2025.155824_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000500716","article-title":"Renal-limited thrombotic microangiopathy due to bevacizumab therapy for metastatic colorectal cancer: a case report","volume":"12","author":"Toriu","year":"2019","journal-title":"Case Rep. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12882-018-1194-9","article-title":"Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report","volume":"20","author":"Yamada","year":"2019","journal-title":"BMC Nephrol."},{"issue":"11","key":"10.1016\/j.prp.2025.155824_bib23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/imj.15061","article-title":"A case of bevacizumab-induced non-remitting thrombotic microangiopathy","volume":"50","author":"Wong","year":"2020","journal-title":"Intern Med. J."},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40618-020-01272-y","article-title":"Proteinuria is a late-onset adverse event in patients treated with cabozantinib","volume":"44","author":"Cappagli","year":"2021","journal-title":"J. Endocrinol. Invest"},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CN110443","article-title":"Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: a case series and systematic review of the literature","volume":"96","author":"Hilburg","year":"2021","journal-title":"Clin. Nephrol."},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.15586\/jkcvhl.v8i1.161","article-title":"Thrombotic microangiopathy associated with pazopanib in a kidney transplant recipient","volume":"8","author":"Kalla","year":"2021","journal-title":"J. Kidney Cancer VHL"},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13730-020-00504-7","article-title":"Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer","volume":"10","author":"Morimoto","year":"2021","journal-title":"CEN Case Rep."},{"issue":"3","key":"10.1016\/j.prp.2025.155824_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-239603","article-title":"A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings","volume":"14","author":"Nakano","year":"2021","journal-title":"BMJ Case Rep."},{"issue":"6","key":"10.1016\/j.prp.2025.155824_bib29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.nefro.2021.08.004","article-title":"Nephrotic syndrome as a manifestation of thrombotic microangiopathy due to long-term use of sunitinib","volume":"42","author":"Nieto-R\u00edos","year":"2022","journal-title":"Nefrol. (Engl. Ed.)"},{"issue":"11","key":"10.1016\/j.prp.2025.155824_bib30","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10157-021-02090-z","article-title":"VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience","volume":"25","author":"Ozawa","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2169\/internalmedicine.9425-22","article-title":"Overlap of thrombotic microangiopathy and mesangial proliferative glomerulonephritis caused by combination therapy with atezolizumab and bevacizumab","volume":"62","author":"Horino","year":"2023","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/clinpract13010018","article-title":"Bevacizumab-induced thrombotic microangiopathy (TMA) in metastatic lung adenocarcinoma patients receiving nivolumab combined with bevacizumab, carboplatin and paclitaxel: two case reports","volume":"13","author":"Hsu","year":"2023","journal-title":"Clin. Pr."},{"key":"10.1016\/j.prp.2025.155824_bib33","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.940906","article-title":"Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: a case report","volume":"24","author":"Padilha","year":"2023","journal-title":"Am. J. Case Rep."},{"issue":"1","key":"10.1016\/j.prp.2025.155824_bib34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/00034894231184942","article-title":"Renal implications of long-term systemic bevacizumab for recurrent respiratory papillomatosis","volume":"133","author":"Robinson","year":"2024","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"issue":"9","key":"10.1016\/j.prp.2025.155824_bib35","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/16.9.1910","article-title":"Association of mesangial IgM with IgM deposits in the macula densa: an indication of non-specific macromolecule transport rather than immune reactant?","volume":"16","author":"Thompson","year":"2001","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.prp.2025.155824_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1357869","article-title":"Urinary complement biomarkers in immune-mediated kidney diseases","volume":"15","author":"Kesarwani","year":"2024","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.prp.2025.155824_bib37","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41401-024-01299-4","article-title":"Bevacizumab induces ferroptosis and enhances CD8+ T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9","volume":"45","author":"Hou","year":"2024","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.prp.2025.155824_bib38","article-title":"Cellular responses to neoadjuvant FOLFOX6-bevacizumab treatment in colorectal cancers analyzed by single-cell transcriptome analysis","volume":"263","author":"Shin","year":"2024","journal-title":"Pathol. Res. Pr."},{"issue":"20","key":"10.1016\/j.prp.2025.155824_bib39","doi-asserted-by":"crossref","first-page":"10958","DOI":"10.3390\/ijms252010958","article-title":"T-cell dynamics predicts prognosis of patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab","volume":"25","author":"Lee","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2025.155824_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10456-022-09863-4","article-title":"Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy","volume":"26","author":"Nowak-Sliwinska","year":"2023","journal-title":"Angiogenesis"},{"key":"10.1016\/j.prp.2025.155824_bib41","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.ki.5000439","article-title":"Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis","volume":"69","author":"Hara","year":"2006","journal-title":"Kidney Int."},{"issue":"46","key":"10.1016\/j.prp.2025.155824_bib42","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322759121","article-title":"VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept","volume":"121","author":"Sharma","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prp.2025.155824_bib43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1538-7836.2008.03212.x","article-title":"Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice","volume":"7","author":"Meyer","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.prp.2025.155824_bib44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10456-018-9598-5","article-title":"Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab","volume":"21","author":"Walraven","year":"2018","journal-title":"Angiogenesis"},{"issue":"8024","key":"10.1016\/j.prp.2025.155824_bib45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-024-07698-1","article-title":"Tumour vasculature at single-cell resolution","volume":"632","author":"Pan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.prp.2025.155824_bib46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.prp.2025.155824_bib47","doi-asserted-by":"crossref","first-page":"14448","DOI":"10.1073\/pnas.0703577104","article-title":"Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions","volume":"104","author":"Advani","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"26","key":"10.1016\/j.prp.2025.155824_bib48","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1038\/onc.2017.1","article-title":"Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy","volume":"36","author":"Castro","year":"2017","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.prp.2025.155824_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41416-024-02725-4","article-title":"PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-\u03b2 pathway","volume":"131","author":"Wang","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2025.155824_bib50","first-page":"1513","article-title":"Lipoprotein glomerulopathy: clinical features and pathological characteristics in Chinese","volume":"117","author":"Chen","year":"2004","journal-title":"Chin. Med. J. (Engl.)"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:26:59Z","timestamp":1778747219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"alternative-id":["S0344033825000160"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.155824","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: A case series and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.155824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155824"}}